For the quarter ending 2026-03-31, ORMP has $268,847K in assets. $13,202K in cash and cash equivalents.
| Balance Sheets | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Cash and cash equivalents | 13,202 | 45,947 | 52,179 | 15,797 |
| Short-term deposits | 11,097 | 10,979 | 4,038 | 22,865 |
| Marketable securities | 4,965 | 5,417 | 4,956 | 1,753 |
| Investments at fair value | 36,576 | 63,551 | 73,514 | 57,525 |
| Convertible note (note 9) | - | 4,636 | - | - |
| Prepaid expenses and other current assets | 2,310 | 2,741 | 1,430 | 1,086 |
| Total current assets | 68,150 | 133,271 | 136,117 | 99,026 |
| Long-term deposits | 2 | 2 | 2 | 2 |
| Marketable securities | 17,967 | 8,371 | - | - |
| Investments at fair value | 50,678 | 10,119 | 11,410 | 8,789 |
| Investment in associate at fair value | 102,299 | 71,623 | 64,803 | 44,298 |
| Loan to an equity method investee | 423 | 553 | 1,044 | 2,529 |
| Investment in lifeward | 22,492 | - | - | - |
| Investment in real estate (note 5) | - | 1,921 | 2,122 | 1,951 |
| Investment in real estate | 1,921 | - | - | - |
| Other non-marketable equity securities | 3,624 | 3,624 | 3,524 | 3,524 |
| Amounts funded in respect of employee rights upon retirement | 46 | 44 | 40 | 38 |
| Property and equipment, net | 561 | 586 | 614 | 645 |
| Operating lease right-of-use assets | 684 | 750 | 817 | 882 |
| Total long-term assets | 200,697 | 97,593 | 84,376 | 62,658 |
| Total assets | 268,847 | 230,864 | 220,493 | 161,684 |
| Accounts payable and accrued expenses | 8,521 | 6,201 | 4,861 | 2,159 |
| Payable to related parties (note 20) | - | 652 | 1 | 34 |
| Deferred income (note 8) | - | 1,353 | 986 | 1,236 |
| Deferred income | 1,471 | - | - | - |
| Dividend payable | 303 | 10,595 | - | - |
| Operating lease liabilities | 268 | 285 | 271 | 264 |
| Total current liabilities | 10,563 | 19,086 | 6,119 | 3,693 |
| Long-term deferred revenues (note 13) | - | 2,000 | 2,000 | 2,000 |
| Long-term deferred income (note 8) | - | 1,269 | 1,496 | 1,724 |
| Deferred income | 1,530 | - | - | - |
| Other liabilities | - | - | - | 0 |
| Employee rights upon retirement | 40 | 39 | 38 | 36 |
| Operating lease liabilities | 493 | 540 | 589 | 648 |
| Dividend payable | 198 | 275 | - | - |
| Deferred tax liabilities | 17,747 | 7,911 | 7,921 | - |
| Total long-term liabilities | 20,008 | 12,034 | 12,044 | 4,408 |
| Common stock, 0.012 par value (60,000,000 authorized shares 40,926,081 and 39,275,006 shares issued and outstanding as of march 31, 2026 and december 31, 2025, respectively) | 491 | 472 | 490 | 491 |
| Additional paid-in capital | 322,906 | 322,708 | 325,367 | 325,008 |
| Accumulated deficit | -85,121 | -123,436 | -122,575 | -170,970 |
| Total stockholders equity | - | 199,744 | 203,282 | 154,529 |
| Non-controlling interests | - | - | -952 | -946 |
| Total equity | 238,276 | 199,744 | 202,330 | 153,583 |
| Total liabilities and equity | 268,847 | 230,864 | 220,493 | 161,684 |
ORAMED PHARMACEUTICALS INC. (ORMP)
ORAMED PHARMACEUTICALS INC. (ORMP)